ஒரையந் குழு நிதி அறிக்கை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஒரையந் குழு நிதி அறிக்கை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஒரையந் குழு நிதி அறிக்கை Today - Breaking & Trending Today

Investegate |Orion Oyj Announcements | Orion Oyj: Orion Group Financial Statement documents 2020, Corporate Governance Statement and Remuneration Report published

A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
1. Obtains access to the information in a personal capacity;
2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so; ....

Eteläuomen Läi , Tuukka Hirvonen , Olli Huotari , Terhi Ormio , Orion Group Financial Statement , Orion Corporation , Corporate Governance Statement , Remuneration Report , Group Financial Statement , Financial Statement , Financial Statements , European Single Electronic Format , Public Accountants , Finnish Accounting Act , Companies Act , Corporate Functions , Investor Relations , Investegate Announcements , Investegate Company Announcements , Orion Oyj , Globe Newswire , Globenewswire And , ஒரையந் குழு நிதி அறிக்கை , ஒரையந் நிறுவனம் , பெருநிறுவன ஆளுகை அறிக்கை , குழு நிதி அறிக்கை ,

Investegate |Orion Oyj Announcements | Orion Oyj: Orion Group Financial Statement Release for 2020

Strong performance amid challenges brought on by COVID-19 pandemic
“The COVID-19 pandemic made 2020 an exceptional and demanding year for Orion and for the world. The strong spike in demand for pharmaceuticals seen in March and April brought challenges to Orion’s production and logistics. However, we prevailed due to the strong commitment and hard work of our people. We strived successfully – and will carry on striving – to ensure that pharmaceuticals manufactured and sold by Orion continue to be available to patients. Our current inventory status is good, but we need to keep working to this effect, as the risk of disruptions in global pharmaceutical supply chains remains higher than usual owing to the pandemic. In the current exceptional circumstances, we have prioritised looking after the health and safety of our employees and ensuring production continuity and patient safety in ongoing clinical trials, and we will continue to do so. Amidst the pandemic, we pushed ou ....

United States , United Kingdom , Eteläuomen Läi , Tuukka Hirvonen , Jari Karlson , Orion Dexdor , Timo Lappalainen , Orion Clevor , Orion Group , Orion Animal Health , Drug Administration , Orion Corporation , Board Of Directors Orion Corporation , Orion Group Financial Statement , Animal Health , Orion Group Financial Statement Release , Group Financial Statement Release , Financial Statement Release , Specialty Products , Senior Vice President , General Meeting , Report January March , Year Financial Report January June , Report January September , Financial Statements , Investor Relations ,

Orion Oyj: Orion Group Financial Statement Release for 2020

Orion Oyj: Orion Group Financial Statement Release for 2020
Orion Group Financial Statement Release for 2020
This is a summary or Orion s Financial Statement Release for 2020. The complete report is attached to this stock exchange release and is available at
https://www.orion.fi/en/Orion-group/investors/financial-reviews-and-presentations/
Net sales totalled EUR 1,078 million (EUR 1,051 million in 2019).
Operating profit was EUR 280 (253) million.
Net sales and operating profit include milestone payments amounting to EUR 42 (51) million.
Profit before taxes was EUR 278 (251) million.
Equity ratio was 67% (77%).
ROCE before taxes was 35% (30%).
ROE after taxes was 29% (26%).
Basic earnings per share were EUR 1.56 (1.43).
Cash flow per share before financial items was EUR 1.85 (1.68). ....

United States , United Kingdom , Eteläuomen Läi , Tuukka Hirvonen , Jari Karlson , Kostenloser Wertpapierhandel , Comtess Comtan , Orion Dexdor , Timo Lappalainen , Orion Clevor , Orion Group , Orion Animal Health , Drug Administration , Orion Corporation , Board Of Directors Orion Corporation , Orion Group Financial Statement , Animal Health , Group Financial Statement Release , Financial Statement Release , Specialty Products , Senior Vice President , General Meeting , Report January March , Year Financial Report January June , Report January September , Financial Statements ,